The FDA has granted clearance to Bot Image’s ProstatID AI software for analysis of non-contrast “short form” magnetic resonance imaging (MRI) scans to screen for prostate cancer.

The AI software eliminates the use of MRI contrast dye that uses gadolinium, a known toxic metal, that can potentially build up in the brain and kidneys with possible side effects.

Eliminating the contrast dye from prostate cancer MRIs enables more frequent, low-cost scans for active surveillance, the company said.

Clinical studies showed that the ProstatID algorithm has an accuracy of 93.6 percent for detection of prostate cancer.

Related Topics